Quantification of abemaciclib and metabolites: evolution of bioanalytical methods supporting a novel oncolytic agent / Enaksha R Wickremsinhe, Lisa B Lee
Aim:Bioanalytical methods undergo many revisions and modifications throughout drug development to meet the objectives of the study and development program.Results:Validated LC–MS/MS methodology used to quantify abemaciclib and four metabolites in human plasma is described. The method, initially validated to support the first-in-human study, was successfully modified to include additional metabolites asin vitroandin vivoinformation about the activity and abundance of human metabolites became available. Consistent performance of the method over time was demonstrated by an incurred sample reanalysis passing rate exceeding 95%, across clinical studies. An overview of the numerous methods involved during the development of abemaciclib, including the quantification of drugs evaluated as combination regimens and used as substrates during drug–drug interaction studies, is presented.Conclusion:Robust bioanalytical methods need to be designed with the flexibility required to support the evolving study objectives associated with registration and post-registration trials. Aim: Results: in vitro in vivo Conclusion.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
Erscheinungsort nicht ermittelbar: 2021 |
| Enthalten in: |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wickremsinhe, Enaksha R [VerfasserIn] |
|---|
| Links: |
FID Access [lizenzpflichtig] |
|---|
| Themen: |
Bioanalysis |
|---|
| Umfang: |
1 Online-Ressource (14 p) |
|---|
| doi: |
10.4155/bio-2021-0039 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
KFL011087226 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | KFL011087226 | ||
| 003 | DE-627 | ||
| 005 | 20230713210610.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230609s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4155/bio-2021-0039 |2 doi | |
| 035 | |a (DE-627)KFL011087226 | ||
| 035 | |a (KFL)prod_FICIBQ_10.4155/bio-2021-0039 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 100 | 1 | |a Wickremsinhe, Enaksha R |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Quantification of abemaciclib and metabolites: evolution of bioanalytical methods supporting a novel oncolytic agent |c Enaksha R Wickremsinhe, Lisa B Lee |
| 264 | 1 | |a [Erscheinungsort nicht ermittelbar] |c 2021 | |
| 300 | |a 1 Online-Ressource (14 p) | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Aim:Bioanalytical methods undergo many revisions and modifications throughout drug development to meet the objectives of the study and development program.Results:Validated LC–MS/MS methodology used to quantify abemaciclib and four metabolites in human plasma is described. The method, initially validated to support the first-in-human study, was successfully modified to include additional metabolites asin vitroandin vivoinformation about the activity and abundance of human metabolites became available. Consistent performance of the method over time was demonstrated by an incurred sample reanalysis passing rate exceeding 95%, across clinical studies. An overview of the numerous methods involved during the development of abemaciclib, including the quantification of drugs evaluated as combination regimens and used as substrates during drug–drug interaction studies, is presented.Conclusion:Robust bioanalytical methods need to be designed with the flexibility required to support the evolving study objectives associated with registration and post-registration trials. Aim: Results: in vitro in vivo Conclusion | ||
| 653 | |a bioanalysis | ||
| 653 | |a clinical sample analysis | ||
| 653 | |a combination drugs | ||
| 653 | |a fit-for-purpose | ||
| 653 | |a incurred sample reanalysis | ||
| 653 | |a metabolites | ||
| 653 | |a oncology | ||
| 653 | |a selectivity | ||
| 700 | 1 | |a Lee, Lisa B |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Bioanalysis |d London : Future Science, 2009 |h Online-Ressource |w (DE-627)KFL000038172 |w (DE-600)2571813-7 |w (DE-576)398101434 |x 1757-6199 |7 nnns |
| 856 | 4 | 0 | |u http://pharmazie.proxy.fid-lizenzen.de/fid/future-medicine-ejournals-pharmazie/doi.org/10.4155/bio-2021-0039 |m X:KFL |x Resolving-System |y FID Access |z lizenzpflichtig |
| 912 | |a GBV_KFL | ||
| 912 | |a FID-PHARM | ||
| 935 | |i IMPORT_0628_prod_FICIBQ_03 | ||
| 951 | |a AR | ||